Per Hellsund News Today

– CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitors –– Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building upon its growing biotherapeutics expertise –ALAMEDA, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXE...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Investegate announcements from Cybrexa Therapeutics, Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting

(0) - Study to determine safety and tolerability of CBX-12 and establish recommended Phase 2 dose - NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex-exatecan), the companys lead therapeutic candidate. The open-l...

Cybrexa Therapeutics Closes $25 Million Series B Financing -Proceeds will advance the companys lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Stre...

(1) - Cybrexa and NCI to collaborate on clinical development of Cybrexas lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors - NEW HAVEN, Conn., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has entered a Cooperative Research and Development Agreement (CRADA) w...

Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (alphalex-exatecan) - No Unexpected Safety Findings During the Course of the Study - - On Track to File an IND in the First Quarter 2021 and Commence Phase I Trial by Mid Year 2021 - NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor target...